BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31153968)

  • 1. Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8
    Chiale C; Moshkani S; Rose JK; Robek MD
    Antiviral Res; 2019 Aug; 168():156-167. PubMed ID: 31153968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.
    Kosinska AD; Johrden L; Zhang E; Fiedler M; Mayer A; Wildner O; Lu M; Roggendorf M
    J Virol; 2012 Sep; 86(17):9297-310. PubMed ID: 22718818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.
    Cobleigh MA; Buonocore L; Uprichard SL; Rose JK; Robek MD
    J Virol; 2010 Aug; 84(15):7513-22. PubMed ID: 20504927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
    Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
    Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.
    Cobleigh MA; Wei X; Robek MD
    J Virol; 2013 Mar; 87(5):2969-73. PubMed ID: 23269785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic and therapeutic HBV vaccination by an HBs-expressing cytomegalovirus vector lacking an interferon antagonist in mice.
    Huang H; Rückborn M; Le-Trilling VTK; Zhu D; Yang S; Zhou W; Yang X; Feng X; Lu Y; Lu M; Dittmer U; Yang D; Trilling M; Liu J
    Eur J Immunol; 2021 Feb; 51(2):393-407. PubMed ID: 33029793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.
    Kawashima K; Isogawa M; Hamada-Tsutsumi S; Baudi I; Saito S; Nakajima A; Tanaka Y
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.
    Obeng-Adjei N; Choo DK; Saini J; Yan J; Pankhong P; Parikh A; Chu JS; Weiner DB
    Cancer Gene Ther; 2012 Nov; 19(11):779-87. PubMed ID: 23037809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence.
    Shen Z; Gao Z; Gu C; Wu J; Wang J; Zhang J; Xie Y; Liu J
    Antiviral Res; 2021 Jun; 190():105076. PubMed ID: 33865876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.
    Kosinska AD; Moeed A; Kallin N; Festag J; Su J; Steiger K; Michel ML; Protzer U; Knolle PA
    Sci Rep; 2019 Jul; 9(1):10808. PubMed ID: 31346211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.
    Cobleigh MA; Bradfield C; Liu Y; Mehta A; Robek MD
    J Virol; 2012 Apr; 86(8):4253-61. PubMed ID: 22345454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.